Crossmark

Afatinib in advanced NSCLC: a profile of its use

Crossref DOI link: https://doi.org/10.1007/s40267-018-0482-6

Published Online: 2018-02-01

Published Print: 2018-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Deeks, Emma D.

Keating, Gillian M.
License Information

Text and Data Mining valid from 2018-02-01
More Information

Article History

First Online: 1 February 2018

Change Date: 16 February 2018

Change Type: Erratum

Change Details: The article ‘Afatinib in advanced NSCLC: a profile of its use’, written by Emma D. Deeks and Gillian M. Keating, was originally published Online First without open access. After Online First publication, Boehringer Ingelheim Pharmaceuticals, Inc. requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Boehringer Ingelheim Pharmaceuticals, Inc. Further details may be foundExternalRef removed. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (ExternalRef removed), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original authors and the source, provide a link to the Creative Commons license and indicate if changes were made.

Compliance with ethical standards

:

: The preparation of this review was not supported by any external funding.

: E. D. Deeks and G. M. Keating are employees of Adis/Springer, are responsible for the article content and declare no conflicts of interest.Additional information about this Adis Drug Review can be found atExternalRef removed.